Novavax files for emergency use listing of COVID-19 vaccine with WHO

"The company has now completed the submission to World Health Organization (WHO) of all modules required for the regulatory evaluation of NVX-CoV2373, the company#39;s recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M adjuvant," Novavax Inc. said